In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stryker in Transition

Executive Summary

For most companies, CEO succession planning is a continuous process. But for Stryker, which has had just three CEOs in its 60-year history and just one in the last 30 years, the changing of the guard is an enormous event.

You may also be interested in...



Taking Stryker Forward: An Interview with Steve MacMillan

A former pharmaceutical executive, Steve McMillan was tapped three years ago to replace John Brown as CEO of Stryker Corp. Following someone who had been in the post 30 years was daunting enough; even more so was continuing the record of strong financial performance that Stryker had maintained throughout its history. In this Interview adapted from the "From the Innovator's Workbench" series sponsored by Stanford University's BioDesign program, McMillan talks about the challenges he faced.

Taking Stryker Forward: An Interview with Steve MacMillan

A former pharmaceutical executive, Steve McMillan was tapped three years ago to replace John Brown as CEO of Stryker Corp. Following someone who had been in the post 30 years was daunting enough; even more so was continuing the record of strong financial performance that Stryker had maintained throughout its history. In this Interview adapted from the "From the Innovator's Workbench" series sponsored by Stanford University's BioDesign program, McMillan talks about the challenges he faced.

Smith & Nephew's Race to the Top

Guess who was the fastest growing orthopedic implant company last year. Smith & Nephew. The boom that has characterized the orthopedics market for the past several years has been a rising tide that lifts all boats--all, that is, except Smith & Nephew. But in the last couple of years, Smith & Nephew has actually been growing faster than their larger competitors. And in an industry that will increasingly see winners and losers, Smith & Nephew believes it is positioned to be one of the winners.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV002247

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel